Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
By N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, M. Puoti, M. Romero‐Gomez, J. Zarski, K. Agarwal, P. Buggisch and 14 more. New England Journal of Medicine, 2014
1,819 citations recorded by the source corpus.
Subfields: Genetics, Hepatology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/5013b1e75644a62a200c9afb4731b1fbbf4f1104
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
Citations in the corpus
- EASL Recommendations on Treatment of Hepatitis C 2018. (2018, background): “In ION-1, treatment-naïve genotype 1a patients, including approximately 15% with compensated cirrhosis, achieved SVR12 in 98% (141/144; one relapse) of cases after 12 weeks of the fixed-dose combination of sofosbuvir and ledipasvir.(74) An integrated analysis of treatment-naïve genotype 1a patients ”
- Molecular Biology of Hepatitis B Virus Infection (2015, positive): “For this among other reasons, a short-term curative therapy, as now available for HCV carriers (Afdhal et al., 2014), is highly desirable, especially one that can be applied at any stage of chronic hepatitis B including the immune tolerant phase.”
- EASL Recommendations on Treatment of Hepatitis C 2015. (2015, background): “The SVR12 rates were 98% (212/217) and 99% (215/217) after 24 weeks of the same combination without or with ribavirin, respectively [34].”
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (2015, neutral): “9 HCV-RNA level 800,000 IU/mL 16 (53) 18 (62) 9 (39) 11 (42) 45 (82) 46 (82) IL28B genotype CC, n (%) 4 (13) 5 (17) 6 (26) 7 (27) 11 (20) 10 (18) Previously treated 22 (73) 19 (66) 11 (48) 18 (69) 39 (71) 48 (86) Regimen received Peg/ribavirin 10 (45) 10 (53) 8 (73) 17 (94) 26 (67) 39 (81) PI þ Peg/”